(TDOC) Teladoc - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US87918A1051

TDOC: Virtual, Medical, Therapy, Counseling, Healthcare, Services

Teladoc Health, Inc. (NYSE: TDOC) is a global leader in delivering virtual healthcare services, operating through two core segments: Teladoc Health Integrated Care and BetterHelp. The Integrated Care segment provides a comprehensive suite of virtual medical services, including general and expert medical care, specialty consultations, chronic condition management, and mental health support. Additionally, it offers enabling technologies and enterprise telehealth solutions tailored for hospitals and health systems. This segment essentially bridges the gap between patients and healthcare providers through digital platforms, ensuring access to care regardless of physical location.

The BetterHelp segment focuses exclusively on mental health, operating a platform that connects individuals with licensed clinicians for counseling and therapy. Services are accessible via website, mobile apps, phone calls, and text-based interactions, making mental health support more accessible and convenient. Teladoc Health serves a diverse range of customers, including employers, health plans, hospitals, insurance companies, and individual members. The company, rebranded from Teladoc, Inc. in 2018, was founded in 2002 and is headquartered in Purchase, New York. Its product offerings are delivered under the Teladoc, Livongo, and BetterHelp brands.

From a financial perspective, Teladoc Health has a market capitalization of approximately $2.3 billion, placing it in the mid-cap category. The company currently operates at a negative trailing P/E ratio, indicating operating losses, though its forward P/E ratio of 357.14 reflects investor expectations of significant future earnings growth. The price-to-book (P/B) ratio of 1.54 suggests that the market values the company slightly above its book value, while the price-to-sales (P/S) ratio of 0.90 indicates a reasonable valuation relative to its revenue. These metrics are critical for investors and fund managers assessing the companys growth potential and valuation in the rapidly evolving telehealth industry.

Additional Sources for TDOC Stock

TDOC Stock Overview

Market Cap in USD 1,631m
Sector Healthcare
Industry Health Information Services
GiC Sub-Industry Health Care Technology
IPO / Inception 2015-07-01

TDOC Stock Ratings

Growth 5y -83.7%
Fundamental -12.7%
Dividend 0.0%
Rel. Strength Industry -42.4
Analysts 3.36/5
Fair Price Momentum 5.23 USD
Fair Price DCF 22.57 USD

TDOC Dividends

No Dividends Paid

TDOC Growth Ratios

Growth Correlation 3m 0.3%
Growth Correlation 12m -34.3%
Growth Correlation 5y -97%
CAGR 5y -40.57%
CAGR/Max DD 5y -0.42
Sharpe Ratio 12m -0.92
Alpha -53.76
Beta 1.18
Volatility 66.91%
Current Volume 4798.2k
Average Volume 20d 8390.8k
What is the price of TDOC stocks?
As of March 15, 2025, the stock is trading at USD 8.62 with a total of 4,798,246 shares traded.
Over the past week, the price has changed by -5.79%, over one month by -39.85%, over three months by -19.29% and over the past year by -41.91%.
Is Teladoc a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Teladoc is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -12.67 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of TDOC as of March 2025 is 5.23. This means that TDOC is currently overvalued and has a potential downside of -39.33%.
Is TDOC a buy, sell or hold?
Teladoc has received a consensus analysts rating of 3.36. Therefor, it is recommend to hold TDOC.
  • Strong Buy: 3
  • Buy: 3
  • Hold: 19
  • Sell: 0
  • Strong Sell: 0
What are the forecast for TDOC stock price target?
According to ValueRays Forecast Model, TDOC Teladoc will be worth about 5.7 in March 2026. The stock is currently trading at 8.62. This means that the stock has a potential downside of -34.45%.
Issuer Forecast Upside
Wallstreet Target Price 10.9 26.3%
Analysts Target Price 11 27%
ValueRay Target Price 5.7 -34.5%